915411-02-8

Basic information

• Product Name: 7-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE
• Synonyms: 1H-Indazole-7-boronic acid pinacol ester;1H-Indazole-7-boronic aci...;7-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole;1H-INDAZOLE, 7-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-;1H-Indazole-7-lboronicacid,pinacolester;indazole 7-pinacol boronate;Indazole-7-boronic acid pinacol ester
• CAS NO: 915411-02-8
• Molecular Formula: C₁₃H₁₇BN₂O₂
• Molecular Weight: 244.1
• Product Categories: Indazole;Organoborons
• Mol File: 915411-02-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 404.123 °C at 760 mmHg
• Flash Point: 198.207 °C
• Appearance: /
• Density: 1.154 g/cm³
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: 7-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(915411-02-8)
• EPA Substance Registry System: 7-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1H-INDAZOLE(915411-02-8)

Safety Data

• Hazardous Substances Data: 915411-02-8(Hazardous Substances Data)

Usage

Uses

Indazole-7-boronic acid, pinacol ester

InChI:InChI=1S/C13H17BN2O2/c1-12(2)13(3,4)18-14(17-12)10-7-5-6-9-8-15-16-11(9)10/h5-8H,1-4H3,(H,15,16)

Upstream product

• 2942-42-9 7-Nitroindazole 
• 21443-96-9 1H-indazol-7-amine 
• 73183-34-3 bis(pinacol)diborane 
• 53857-58-2 7-bromo-1H-indazole 
• 186407-74-9 4-bromoindazole 

Downstream Products

• 915411-01-7 (1H-indazol-7-yl)boronic acid 

Relevant articles and documents

ORGANIC COMPOUNDS AND ORGANIC ELECTRO LUMINESCENCE DEVICE COMPRISING THE SAME

The present invention relates to organic compounds and an organic electroluminescent device comprising the same. According to the present invention, the organic compounds can improve light emitting efficiency, driving voltage, lifespan, etc. of the organic electroluminescent device by being used in an organic layer, desirably a light emitting layer of the organic electroluminescent device. The compounds are represented by chemical formula 1.COPYRIGHT KIPO 2015

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.